New Risk • May 21
New major risk - Revenue and earnings growth Earnings have declined by 0.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Duyuru • Apr 25
Caregen Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Caregen Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Reported Earnings • Mar 20
Full year 2025 earnings released: EPS: ₩411 (vs ₩658 in FY 2024) Full year 2025 results: EPS: ₩411 (down from ₩658 in FY 2024). Revenue: ₩72.8b (down 12% from FY 2024). Net income: ₩20.1b (down 38% from FY 2024). Profit margin: 28% (down from 39% in FY 2024). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings. Duyuru • Mar 10
Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026 Caregen Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:30 Tokyo Standard Time. Location: conference room, 24, yeongdong-daero 65-gil, gangnam-gu, seoul South Korea New Risk • Jan 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Nov 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Sep 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩50,400, the stock trades at a trailing P/E ratio of 78.9x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 90% over the past three years. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₩48,200, the stock trades at a trailing P/E ratio of 75.4x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 159% over the past three years. New Risk • Jul 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 100% Paying a dividend despite having no free cash flows. High level of non-cash earnings (73% accrual ratio). Upcoming Dividend • Jun 20
Upcoming dividend of ₩240 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 21 July 2025. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (1.0%). New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 97% Paying a dividend despite having no free cash flows. High level of non-cash earnings (63% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Buy Or Sell Opportunity • May 12
Now 25% overvalued Over the last 90 days, the stock has fallen 1.5% to ₩30,550. The fair value is estimated to be ₩24,440, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 33%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 89% in the next 2 years. Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Independent Outside Director Seong-Wook Heo was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Mar 21
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: ₩658 (down from ₩813 in FY 2023). Revenue: ₩82.6b (up 4.3% from FY 2023). Net income: ₩32.3b (down 19% from FY 2023). Profit margin: 39% (down from 50% in FY 2023). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 12
Caregen Co., Ltd., Annual General Meeting, Mar 25, 2025 Caregen Co., Ltd., Annual General Meeting, Mar 25, 2025, at 09:30 Tokyo Standard Time. Location: conference room, 16-27, ls-ro 91beon-gil, dongan-gu, gyeonggi-do, anyang South Korea New Risk • Feb 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 121% Paying a dividend despite having no free cash flows. High level of non-cash earnings (68% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Buy Or Sell Opportunity • Feb 06
Now 32% overvalued after recent price rise Over the last 90 days, the stock has risen 101% to ₩33,950. The fair value is estimated to be ₩25,767, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Duyuru • Feb 03
Caregen Co., Ltd. to Report Q4, 2024 Results on Feb 10, 2025 Caregen Co., Ltd. announced that they will report Q4, 2024 results on Feb 10, 2025 Buy Or Sell Opportunity • Jan 03
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 62% to ₩31,750. The fair value is estimated to be ₩25,767, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 61% in the next 2 years. Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩28,500, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past three years. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩23,150, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years. Duyuru • Nov 08
Caregen Co., Ltd. to Report Q3, 2024 Results on Nov 11, 2024 Caregen Co., Ltd. announced that they will report Q3, 2024 results on Nov 11, 2024 Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩18,550, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. New Risk • Aug 26
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 93% The company is paying a dividend despite having no free cash flows. Dividend yield: 5.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 93% Paying a dividend despite having no free cash flows. High level of non-cash earnings (70% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change). Major Estimate Revision • Aug 06
Consensus EPS estimates fall by 18% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩93.0m to ₩85.1m. EPS estimate also fell from ₩907 per share to ₩747 per share. Net income forecast to grow 9.7% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩24,000 to ₩14,000. Share price fell 29% to ₩16,240 over the past week. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 28% After last week's 28% share price decline to ₩16,240, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change). Duyuru • Aug 01
Caregen Co., Ltd. to Report First Half, 2024 Results on Aug 02, 2024 Caregen Co., Ltd. announced that they will report first half, 2024 results on Aug 02, 2024 Reported Earnings • May 18
First quarter 2024 earnings released: EPS: ₩194 (vs ₩288 in 1Q 2023) First quarter 2024 results: EPS: ₩194 (down from ₩288 in 1Q 2023). Revenue: ₩20.4b (down 17% from 1Q 2023). Net income: ₩9.52b (down 33% from 1Q 2023). Profit margin: 47% (down from 57% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • May 01
Caregen Co., Ltd. to Report Q1, 2024 Results on May 10, 2024 Caregen Co., Ltd. announced that they will report Q1, 2024 results on May 10, 2024 Reported Earnings • Mar 15
Full year 2023 earnings released: EPS: ₩813 (vs ₩556 in FY 2022) Full year 2023 results: EPS: ₩813 (up from ₩556 in FY 2022). Revenue: ₩79.2b (up 15% from FY 2022). Net income: ₩39.9b (up 46% from FY 2022). Profit margin: 50% (up from 40% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩26,200, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 111% over the past three years. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩25,350, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 92% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩340 per share at 2.0% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 05 April 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%). Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩199 (vs ₩128 in 3Q 2022) Third quarter 2023 results: EPS: ₩199 (up from ₩128 in 3Q 2022). Revenue: ₩18.7b (up 2.2% from 3Q 2022). Net income: ₩9.80b (up 56% from 3Q 2022). Profit margin: 52% (up from 34% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩24,000, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 101% over the past three years. Duyuru • Nov 01
Caregen Co., Ltd. to Report Q3, 2023 Results on Nov 10, 2023 Caregen Co., Ltd. announced that they will report Q3, 2023 results on Nov 10, 2023 Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩31,400, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 176% over the past three years. Buying Opportunity • Sep 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be ₩50,401, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 123% in 2 years. Earnings is forecast to grow by 153% in the next 2 years. Price Target Changed • Aug 25
Price target increased by 7.4% to ₩58,000 Up from ₩54,000, the current price target is provided by 1 analyst. New target price is 48% above last closing price of ₩39,250. Stock is up 56% over the past year. The company is forecast to post earnings per share of ₩946 for next year compared to ₩278 last year. Duyuru • Jul 29
Caregen Co., Ltd. to Report Q2, 2023 Results on Aug 09, 2023 Caregen Co., Ltd. announced that they will report Q2, 2023 results on Aug 09, 2023 Buying Opportunity • Jul 03
Now 24% undervalued Over the last 90 days, the stock is up 10.0%. The fair value is estimated to be ₩310,506, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 30%. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 171% in the next 2 years. Upcoming Dividend • Jun 22
Upcoming dividend of ₩1,000 per share at 1.2% yield Eligible shareholders must have bought the stock before 29 June 2023. Payment date: 20 July 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.2%). In line with average of industry peers (1.2%). New Risk • Jun 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 156% Cash payout ratio: 119% Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩227,500, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 12x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 233% over the past three years. Reported Earnings • May 10
First quarter 2023 earnings released: EPS: ₩1,440 (vs ₩768 in 1Q 2022) First quarter 2023 results: EPS: ₩1,440 (up from ₩768 in 1Q 2022). Revenue: ₩24.7b (up 61% from 1Q 2022). Net income: ₩14.1b (up 88% from 1Q 2022). Profit margin: 57% (up from 49% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 54% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩213,500, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 117% over the past year. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩201,500, the stock trades at a trailing P/E ratio of 72.6x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 249% over the past year. Reported Earnings • Mar 18
Full year 2022 earnings released: EPS: ₩2,778 (vs ₩2,582 in FY 2021) Full year 2022 results: EPS: ₩2,778 (up from ₩2,582 in FY 2021). Revenue: ₩69.1b (up 17% from FY 2021). Net income: ₩27.3b (up 7.7% from FY 2021). Profit margin: 40% (down from 43% in FY 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₩180,000, the stock trades at a trailing P/E ratio of 68.7x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 189% over the past year. Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improved over the past week After last week's 18% share price gain to ₩145,000, the stock trades at a trailing P/E ratio of 55.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 126% over the past year. Upcoming Dividend • Dec 21
Upcoming dividend of ₩1,500 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. The company is paying out more than 100% of its profits and is paying out 75% of its cash flow. Trailing yield: 2.0%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 19% share price gain to ₩128,100, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 104% over the past year. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: ₩640 (vs ₩669 in 3Q 2021) Third quarter 2022 results: EPS: ₩640 (down from ₩669 in 3Q 2021). Revenue: ₩18.3b (up 34% from 3Q 2021). Net income: ₩6.28b (down 4.3% from 3Q 2021). Profit margin: 34% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: ₩640 (vs ₩669 in 3Q 2021) Third quarter 2022 results: EPS: ₩640 (down from ₩669 in 3Q 2021). Revenue: ₩18.3b (up 34% from 3Q 2021). Net income: ₩6.28b (down 4.3% from 3Q 2021). Profit margin: 34% (down from 48% in 3Q 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 27% share price gain to ₩116,900, the stock trades at a trailing P/E ratio of 44.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 80% over the past year. Valuation Update With 7 Day Price Move • Oct 21
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩95,600, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩119,400, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 73% over the past year. Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improved over the past week After last week's 17% share price gain to ₩144,400, the stock trades at a trailing P/E ratio of 54.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 98% over the past year. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment improved over the past week After last week's 16% share price gain to ₩110,500, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 68% over the past year. Upcoming Dividend • Jun 22
Upcoming dividend of ₩800 per share Eligible shareholders must have bought the stock before 29 June 2022. Payment date: 20 July 2022. Payout ratio is on the higher end at 90%, however this is supported by cash flows. Trailing yield: 2.5%. Lower than top quartile of South Korean dividend payers (3.2%). Higher than average of industry peers (1.0%). Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorated over the past week After last week's 20% share price decline to ₩104,000, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 71% over the past year. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 31% share price gain to ₩126,000, the stock trades at a trailing P/E ratio of 48.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 82% over the past three years. Valuation Update With 7 Day Price Move • Mar 29
Investor sentiment improved over the past week After last week's 40% share price gain to ₩97,200, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 16% share price gain to ₩65,000, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 6.1% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩1,300 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is on the higher end at 87%, however this is supported by cash flows. Trailing yield: 2.4%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Upcoming Dividend • Jun 23
Upcoming dividend of ₩700 per share Eligible shareholders must have bought the stock before 29 June 2021. Payment date: 24 July 2021. Trailing yield: 3.0%. Within top quartile of South Korean dividend payers (2.1%). Higher than average of industry peers (0.6%). Duyuru • Jan 31
Caregen Co., Ltd. to Report Fiscal Year 2020 Results on Feb 10, 2021 Caregen Co., Ltd. announced that they will report fiscal year 2020 results on Feb 10, 2021 Is New 90 Day High Low • Jan 05
New 90-day high: ₩76,300 The company is up 23% from its price of ₩62,200 on 07 October 2020. The South Korean market is also up 23% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 16% over the same period. Is New 90 Day High Low • Dec 09
New 90-day high: ₩71,400 The company is up 11% from its price of ₩64,100 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 20
New 90-day high: ₩66,400 The company is up 8.0% from its price of ₩61,700 on 21 August 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Oct 15
New 90-day low: ₩60,400 The company is down 14% from its price of ₩69,900 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. 
